WARMINSTER, Pa., May 22, 2024 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with.
Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001.
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its.